Vetter Begins Building New Manufacturing Facility in Germany
Vetter, a globally recognized Contract Development and Manufacturing Organization specializing in aseptic filling and pharmaceutical manufacturing services, has officially launched construction activities for its newest production facility in Saarlouis, Germany. The milestone was commemorated with a traditional groundbreaking ceremony attended by company executives, political leaders, regional officials, and industry stakeholders, marking a major step forward in the company’s long-term global expansion strategy.
The new Saarlouis location represents one of the largest investments in the company’s history and highlights Vetter’s commitment to strengthening its position as a leading partner for the pharmaceutical and biotechnology industries. During the initial development phase, the company plans to construct a highly advanced manufacturing facility dedicated to the commercial production of injectable medicines. The site, which spans approximately 95 acres, is expected to become a major hub for the production of innovative and complex drug products over the coming years.
Vetter announced that it intends to invest nearly half a billion euros into the Saarlouis project by the time the facility is scheduled to become operational in 2031. The substantial investment reflects the growing demand for high-quality aseptic manufacturing services across the global pharmaceutical sector, particularly for biologics, injectable therapies, and other advanced medicines requiring sophisticated production technologies and stringent quality standards.
The company’s expansion project is also expected to have a major economic impact on the Saarland region. Once operational, the new facility is projected to create between 400 and 500 jobs during the initial stages of operation. Over time, employment opportunities could increase significantly, reaching as many as 1,500 positions by the final stage of the first construction phase. Looking further ahead, the full development potential of the site could ultimately support up to 2,000 jobs, making the facility one of the region’s most important industrial and economic development initiatives.
As part of the first expansion phase, Vetter plans to build a manufacturing complex covering approximately 50,000 square meters. In addition to the core production building, the site will include multiple supporting facilities such as laboratories, warehousing infrastructure, and other production-related operational units designed to support large-scale pharmaceutical manufacturing activities.
At the heart of the project will be three advanced cleanrooms dedicated to aseptic filling operations. Two of these cleanrooms are being designed specifically for filling pre-sterilized syringes, while the third will support vial filling operations. These cleanrooms will incorporate modern pharmaceutical manufacturing technologies aimed at ensuring high efficiency, sterility assurance, and compliance with international regulatory standards. The infrastructure is expected to support the production of innovative therapies and increasingly complex injectable medicines that are becoming more important across modern healthcare systems.
During the groundbreaking ceremony, members of the Vetter leadership team emphasized the strategic significance of the project for the company’s future growth and long-term competitiveness.
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the Vetter owner family, described the groundbreaking as a defining moment for the family-owned company. He noted that the Saarlouis investment represents an important milestone in Vetter’s efforts to create sustainable long-term growth opportunities while further expanding manufacturing capacity for complex pharmaceutical products.
According to Udo J. Vetter, the new site will allow the company to continue providing international pharmaceutical and biotechnology customers with the high-quality manufacturing resources and reliability that have become closely associated with the Vetter brand. He highlighted the company’s long-standing focus on quality, operational excellence, and customer trust as key drivers behind the expansion initiative.
Political leaders attending the event also praised the investment as a transformative opportunity for the region’s economy and industrial future.
Anke Rehlinger, Minister President of Saarland, described the groundbreaking ceremony as a positive and important moment for the state. She emphasized that the arrival of a strong and innovative pharmaceutical manufacturing company like Vetter would create new economic opportunities for both Saarlouis and the broader Saarland region. Rehlinger also stated that the project demonstrates how successful structural transformation can be achieved when governments and industries work together proactively to shape future economic development.
Jürgen Barke, Saarland’s Minister of Economic Affairs, Innovation, Digitalization and Energy, also underscored the strategic importance of the investment. He explained that a high-technology pharmaceutical manufacturing project of this scale significantly enhances Saarland’s attractiveness as a destination for advanced industrial investment. According to Barke, the project will contribute to the development of sustainable and future-oriented employment opportunities while strengthening the region’s reputation within the global pharmaceutical industry.
Barke further noted that the investment could generate broader economic ripple effects across the region, supporting suppliers, infrastructure development, innovation ecosystems, and workforce growth in related industries. The project is therefore expected to play a central role in Saarland’s ongoing industrial transformation and economic modernization efforts.
The Saarlouis expansion forms part of Vetter’s broader global investment strategy aimed at supporting rising market demand for injectable pharmaceutical products and expanding the company’s international manufacturing footprint. For more than 75 years, Vetter has built a reputation for delivering high-quality aseptic manufacturing services to pharmaceutical and biotechnology companies around the world. The company has become particularly well known for its expertise in handling sensitive and complex drug products that require advanced filling technologies and rigorous quality assurance systems.
To keep pace with evolving industry requirements and increasing demand for injectable therapies, Vetter has continued investing heavily in production infrastructure across multiple international locations, including facilities in Germany, Austria, and the United States. The addition of the Saarlouis site represents another significant step in the company’s long-term strategy to expand production capabilities and strengthen supply reliability for customers worldwide.
The pharmaceutical industry continues to experience strong growth in demand for injectable therapies, including biologics, cell and gene therapies, and specialized treatments for chronic and rare diseases. As pharmaceutical companies increasingly outsource manufacturing operations to specialized CDMOs, companies like Vetter are playing an increasingly important role in ensuring that advanced therapies can be produced safely, efficiently, and at commercial scale.
With construction now officially underway, the Saarlouis project is expected to become a cornerstone of Vetter’s future operations. The facility will not only expand the company’s manufacturing capacity but also reinforce its position as a leading global partner for the development and production of injectable medicines. Through its significant investment in advanced infrastructure, technology, and workforce development, Vetter is positioning itself to support the next generation of pharmaceutical innovation while contributing to long-term economic growth in the Saarland region.
About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,300 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital.
The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen.
The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award andtherecognitionof Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day.
